1 citations
,
August 2022 in “JAAD case reports” Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
1 citations
,
November 2021 in “CRC Press eBooks” Common hair loss in men can be treated with minoxidil or finasteride.
Baldness is often hereditary and linked to male hormones, becoming noticeable when half the hair is lost.
30 citations
,
May 2018 in “Experimental Dermatology” The conclusion is that future hair loss treatments should target the root causes of hair thinning, not just promote hair growth.
58 citations
,
October 1993 in “International Journal of Dermatology” Minoxidil helps hair growth and reduces shedding in women.
11 citations
,
April 1990 in “Australasian Journal of Dermatology” Minoxidil modestly increases hair growth in men with early baldness and is safe to use.
16 citations
,
July 1988 in “International Journal of Dermatology” A 48-week double-blind study involving 428 patients evaluated the safety and efficacy of a 2% minoxidil solution for treating male pattern baldness. Initially, patients received either the minoxidil solution or a placebo for 24 weeks, after which placebo patients switched to minoxidil. By the end of the placebo-controlled period, 384 patients were evaluable, and 329 completed the study. Results showed that the 2% minoxidil group had a significantly higher mean nonvellus hair count compared to the placebo group (p = 0.0187) and a greater increase in nonvellus hair from baseline to week 24 (p = 0.0385). From weeks 24 to 48, both groups experienced a significant increase in nonvellus hair count. Assessments by patients and investigators indicated significant differences in hair growth between treatments at week 24, with more hair growth observed in the minoxidil group.
26 citations
,
January 1987 in “Dermatology” A 48-week study conducted in France, West Germany, and the UK evaluated the efficacy and safety of 2% topical minoxidil for early male-pattern baldness. At week 24, 225 patients were assessed, with 116 in the treatment group and 109 in the placebo group. The minoxidil group showed significant improvements in non-vellus hair counts and hair growth evaluations compared to placebo, with no significant differences in blood pressure, pulse, or weight changes. Dermatological side effects were mild. From weeks 24 to 48, all patients received minoxidil, resulting in further hair growth, with 32.7% showing moderate or dense new hair growth by week 48. The study concluded that topical minoxidil was a safe and effective treatment for some patients with early male-pattern baldness, though further research was needed to identify likely responders.
